<scp>D</scp>epression in male patients on methadone maintenance therapy

Baharudin, Azlin; Mislan, Noormazita; Ibrahim, Normala; Sidi, Hatta; Jaafar, Nik Ruzyanei Nik

doi:10.1111/appy.12069

Cited by 21 publications

(17 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Numbers of factors such as methadone dosage, methadone duration, age group of the patients, time of assessment, depression, and definition of sexual dysfunction were different across the studies. Such factors could have been the confounding factors that affected the prevalence rate [42][43][44]. Furthermore, studies that were reviewed were of variable quality, and seven of them were rated as having medium-to-high risk of bias (Table 3).…”

Section: Comparison Of Prevalence Ratesmentioning

confidence: 99%

The Prevalence of Sexual Dysfunction among Male Patients on Methadone and Buprenorphine Treatments: A Meta-Analysis Study

Yee

Loh

Hashim

et al. 2014

The Journal of Sexual Medicine

View full text Add to dashboard Cite

Introduction For many years, methadone has been recognized as an effective maintenance treatment for opioid dependence. However, of the many adverse events reported, sexual dysfunction is one of the most common side effects. Aim We conducted a meta-analysis to evaluate the prevalence of sexual dysfunction among male patients on methadone and buprenorphine treatments. Methods Relevant studies published from inception until December 2012 were identified by searching PubMed, OVID, and Embase. Studies were selected using prior defined criteria. Heterogeneity, publication bias, and odds ratio were assessed thoroughly. Main Outcome Measures To examine the prevalence and odds ratio of sexual dysfunctions among the methadone and buprenorphine groups. Results A total of 1,570 participants from 16 eligible studies were identified in this meta-analysis. The studies provided prevalence estimates for sexual dysfunction among methadone users with a meta-analytical pooled prevalence of 52% (95% confidence interval [CI], 0.39–0.65). Only four studies compared sexual dysfunction between the two groups, with a significantly higher combined odds ratio in the methadone group (OR = 4.01, 95% CI, 1.52–10.55, P = 0.0049). Conclusions Evidence showed that the prevalence of sexual dysfunction was higher among the users of methadone compared with buprenorphine. Patients with sexual difficulty while on methadone treatment were advised to switch to buprenorphine.

show abstract

Section: Comparison Of Prevalence Ratesmentioning

confidence: 99%

The Prevalence of Sexual Dysfunction among Male Patients on Methadone and Buprenorphine Treatments: A Meta-Analysis Study

Yee

Loh

Hashim

et al. 2014

The Journal of Sexual Medicine

View full text Add to dashboard Cite

show abstract

“…Few such studies have been conducted among MMT users (Madden, Lea, Bath, & Winstock, 2008) and none have been conducted in China. Other factors of depression among MMT users include education, employment status, social support, and family relationships (Baharudin, Mislan, Ibrahim, Sidi, & Nik Jaafar, 2013; Nyamathi et al, 2012; Wang et al, 2012; Weissman, Slobetz, Prusoff, Mezritz, & Howard, 1976). Such factors were also associated with suicidal ideation as depression is a strong predictor of suicidal ideation (Britton & Conner, 2010).…”

Section: Introductionmentioning

confidence: 99%

Depression, suicidal ideation, and related factors of methadone maintenance treatment users in Guangzhou, China

Xiao

et al. 2016

AIDS Care

View full text Add to dashboard Cite

Mental health problems are prevalent among drug users. Methadone maintenance treatment (MMT) is an evidence-based effective treatment for drug addiction; however, there are few studies investigating depression, suicidal ideation, and their related factors among MMT users. In this cross-sectional study, 648 MMT users were recruited from six MMT clinics in Guangzhou, China. Data were collected through face-to-face interviews by trained interviewers. Of all participants, 270 (42.7%) exhibited probable depression (Depression Subscale of the Chinese short version of Depression, Anxiety, and Stress Scale (DASS-D), score ≥ 10) and 99 (15.3%) reported having suicidal ideation in the last six months. After adjusting for significant socio-demographic characteristics, all studied variables, including drug use history, social support, family support for MMT use, and satisfaction toward MMT services were significantly associated with both probable depression and suicidal ideation in the last six months. Furthermore, depression fully mediated the associations between drug use history, satisfaction toward MMT services, and suicidal ideation. In the final multivariate models, probable depression was associated with social support (OR = 0.88, 95% CI = 0.83–0.93) and satisfaction toward MMT services provided by doctors (OR = 0.59, 95% CI = 0.40–0.86), while for suicidal ideation, social support (OR = 0.85, 95% CI = 0.78–0.92) and probable depression (OR = 5.94, 95% CI = 3.39–10.42) were significant. The findings suggest that there are unmet mental health needs among MMT users. For countries with limited resources of psychological services, mental health care toward MMT users should be implanted into current health care settings and incorporate components such as social support, family’s understanding of MMT, and service satisfaction.

show abstract

“…Fifty percent of those on methadone maintenance therapy were found to be suffering from depression 12 . It may be a driving force in motivating opiate-dependent individuals seek treatment 13 , particularly as depression is one of the prime causes of drug addiction relapse 14 . Some antidepressants like Sertraline 15 and Venlafaxine 16 and substances with antidepressant activity such as Berberine 17 and Saffron extract 18 are effective in delaying or reducing addiction relapse irrespective of methadone administration.…”

Section: Introductionmentioning

confidence: 99%

Administration of venlafaxine after chronic methadone detoxification blocks post-depression relapse in rats

Fadaei-Kenarsary

Moghaddam

Mansouri

et al. 2017

Braz. arch. biol. technol.

View full text Add to dashboard Cite

Relapse is highly prevalent after detoxification and depression. Due to the advantages of venlafaxine compared with other antidepressants, it is expected that venlafaxine administration may reduce relapse after detoxification and depression. This study aimed to evaluate the effects of venlafaxine on depression-induced relapse to morphine dependence after methadone detoxification. Eighty Sprague-Dawley rats were habituated and conditioned with morphine (10 mg/kg, S.C., for 4 days). After that, primary forced swimming and conditioned place preference (CPP) were tested. They were followed by methadone (70 mg/kg/day, P.O., for 7 days) administration, extinguishing, forced swimming stress (FSS) and administration of venlafaxine (80 mg/kg/day, I.P., for 7 days). Finally same tests were performed. Administration of venlafaxine resulted in a decrement in final preference scores associated with a prime morphine injection (PMI) compared to the primary scores in methadone treated (MTD+) animals. In a swimming test, venlafaxine increased the amount of final floating and decreased final activity scores compared with the primary scores after administration of methadone. Venlafaxine reduced locomotor activity in MTD+ animals in the final test with PMI. There was a positive correlation between the final activity and preference scores after PMI. In conclusion, venlafaxine improved anxiety and depression-induced relapse on methadone detoxified rats.

show abstract

Depression in male patients on methadone maintenance therapy

Cited by 21 publications

References 29 publications

The Prevalence of Sexual Dysfunction among Male Patients on Methadone and Buprenorphine Treatments: A Meta-Analysis Study

The Prevalence of Sexual Dysfunction among Male Patients on Methadone and Buprenorphine Treatments: A Meta-Analysis Study

Depression, suicidal ideation, and related factors of methadone maintenance treatment users in Guangzhou, China

Administration of venlafaxine after chronic methadone detoxification blocks post-depression relapse in rats

Contact Info

Product

Resources

About